Zacks' 7 Best Stocks for June, 2013
FREE Report for Zacks.com
Visitors Only

They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.

Today, you can see them free.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 06/18/2013

Company Name Symbol %Change
STAAR SURGIC STAA
10.98%
LUMOS NETWOR LMOS
5.70%
INSTEEL IND IIIN
5.28%
ERICKSON AIR EAC
5.10%
ASSURED GUAR AGO
4.98%

West Sets Up New Facility in India

by Zacks Equity Research

August 24, 2012 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

West Pharmaceutical Services’ (WST - Snapshot Report) indirect subsidiary, West Pharmaceutical India Packaging Private Ltd., has commenced the construction of a new compression molding facility in Sri City, India. The facility will be a quantum of the company’s global logistics of its remarkable international standard pharmaceutical packaging components.

Earlier this year, West Pharmaceutical forged a contract to lease an area of 72,800 square meters for 99 years in Sri City Special Economic Zone (SEZ). Sri City boasts of an urban location with special benefits of an SEZ, was selected on the basis of availability of utilities, appropriateness of labor, supply chain facility and living standards, among others.

The first plant in India underlines the company’s focus on business expansion in Asia. According to the company, the Indian facility will support its effort to meet the dynamic and burgeoning market demand, especially in the Asia Pacific region. The move is also expected to form an accord with the projected consumer base of West Pharmaceutical in India.

The construction of Phase 1 of the facility, which will manufacture metal and elastomeric pharmaceutical components to be used in the packaging of the company’s injectable medicines, has already begun. The set-up area of Phase 1 is 15,300 square meters. The commercial production of metal components is not expected to begin before the first quarter of 2014, while production of a variety of premium elastomeric components is expected to commence in the first quarter of 2015.

Manufacture of ready-to-use sterilized components will actualize in 2016. Construction of Phase 3 is expected to complete in 2023 with a total built-up area of 37,700 square meters.

Per management, the new plant will facilitate timely supply to the company’s customers in India. Also, West Pharmaceutical will be able to monitor its costs of production based on the improved global supply chain as well as process engineering know-how.

West Pharmaceutical is a global leader in the provision of drug administration systems and components for packaging as well as delivery of injectable drugs and delivery system components across various industries. Its compression molding facility in China is under construction and is expected to be completed at the end of 2012.

West Pharmaceutical has a significant competitive advantage in the market it serves. Additionally, it continues to make headway into new geographies to expand its business.

However, macroeconomic pressure across the globe remains a headwind.

West Pharmaceutical, which competes with 3M Co. (MMM - Analyst Report) and Rexam plc. (REXMY) in certain niches, currently has a Zacks#2 Rank, which translates into a short-term Buy rating.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.